HUTCHMED (China) Limited

<!-- Name:DistributionId Value:8786594 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8778097 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8777159 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8738707 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S.,…

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal…

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and…

Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED…

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically…